STA
CORT icon

Summit Trail Advisors’s Corcept Therapeutics CORT Stock Holding History

Summit Trail Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$389K Buy
+9,660
New +$361K 0.01% 1243
2025
Q4 		– Sell
-3,148
Closed -$262K – 1323
2025
Q3 		$262K Buy
+3,148
New +$228K ﹤0.01% 1235

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Summit Trail Advisors's CORT Position: Q1 2026 in Review

Summit Trail Advisors opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 9,660 shares worth $389K. The stake represents 0.01% of the portfolio and ranks #1243 among its holdings. This is a return to the name: Summit Trail Advisors previously reported a position in CORT as recently as Q3 2025.

Summit Trail Advisors first reported a position in CORT in Q3 2025 and has held it in 2 quarters since. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Summit Trail Advisors held 9,660 shares of Corcept Therapeutics worth $389K as of Q1 2026.
  • Corcept Therapeutics was a new Summit Trail Advisors position in Q1 2026.
  • Corcept Therapeutics made up 0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1243 holding.
  • Summit Trail Advisors first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.